Tous Actualités
Suivre
Abonner Epigenomics AG

Epigenomics AG

EANS-News: Warnex Launches Colorectal Cancer Blood Testing Service in Canada Using Epigenomics' Septin9 Biomarker

  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
Company Information/Molecular diagnostics
Berlin, Germany, and Laval, QC, Canada, December 6, 2010 (euro adhoc)
- Epigenomics AG (Frankfurt Prime Standard: ECX), a cancer molecular 
diagnostics company and Warnex Medical Laboratories, a division of 
Warnex Inc. (TSX: WNX), today announced the launch of a molecular 
diagnostic blood testing service for colorectal cancer in Canada, 
based on Epigenomics' patented biomarker Septin9 and DNA methylation 
technologies. Warnex is the first laboratory to offer Septin9 testing
in Canada, after obtaining the non-exclusive rights from Epigenomics 
in May 2010. Prior to its launch, Warnex's Septin9 test was 
independently developed and successfully validated using clinical 
blood samples from colorectal cancer patients and individuals with no
apparent disease as verified by colonoscopy.
"Colorectal cancer is curable if caught early enough and blood tests 
like this may play an important role in saving lives. We are 
delighted that patients in Canada will now also be able to benefit 
from Septin9 testing, alongside patients in the United States, Europe
and the Middle East," commented Geert Nygaard, Chief Executive 
Officer of Epigenomics.
"We are pleased to add this colorectal cancer test based on real-time
PCR technology to our service offering as part of our continued 
commitment to delivering the most advanced specialized diagnostic 
services to Canadian healthcare professionals," said Mark Busgang, 
President and CEO of Warnex. "The Septin9 test is a convenient and 
specific blood test for colorectal cancer detection that can easily 
be integrated into the patient's routine physical, as it is 
non-invasive and does not require any drug or dietary restrictions."
Colorectal cancer is the second-leading cause of cancer deaths in 
Canada. In 2009, an estimated 22,000 Canadians were diagnosed with 
the disease and 9,100 died from it. As colorectal cancer is largely 
curable when detected in early, still localized stages, the 
Colorectal Cancer Association of Canada recommends that all Canadians
age 50 and over undergo screening with a test detecting blood in 
stool (fecal occult blood test or fecal immunochemical test) at least
once every two years. If a test is positive for blood, a colonoscopy 
should be performed to determine the cause of bleeding. Despite the 
clear benefits of colorectal cancer screening in reducing mortality 
from this disease, only 4% to 14% of eligible Canadians follow the 
screening recommendations. Innovative convenient screening methods 
could greatly increase compliance with current guidelines and thereby
contribute to reducing mortality from colorectal cancer.
Note to the editor
To view the brochure for Warnex's Septin9 Blood Test, please follow 
this link: http://www.warnex.ca/docs/Septin9.pdf
Contact Epigenomics AG
Dr. Achim Plum
Sen. VP Corporate Development
Epigenomics AG
Tel +49 (0) 30 24345 368 
pr@epigenomics.com
www.epigenomics.com
Contact Warnex
Catherine Sartoros
Communications Specialist
Warnex Inc.
+1 450-663-6724 x 277 
csartoros@warnex.ca
About Epigenomics
Epigenomics AG is a molecular diagnostics company with a focus on the
development of novel products for cancer. Using DNA methylation 
biomarkers, Epigenomics' tests on the market and in development for 
colorectal, lung, and prostate cancer aim at aiding in an earlier and
more accurate diagnosis of these diseases, thereby potentially 
increasing the patient's chances of survival.
For development and global commercialization of IVD test products, 
Epigenomics pursues a dual business strategy in which direct 
commercialization of proprietary diagnostic test products is combined
with non-exclusive licensing to diagnostic industry players with 
broad customer access. Strategic diagnostics industry partners 
include Abbott Molecular, Sysmex Corporation, Quest Diagnostics 
Incorporated, ARUP Laboratories, Inc., and Warnex Laboratories, Inc. 
for diagnostics test products and services, and QIAGEN N.V. for 
sample preparation solutions and research products. The company is 
headquartered in Berlin, Germany, and has a wholly owned subsidiary, 
Epigenomics Inc., in Seattle, WA, USA. For more information, please 
visit Epigenomics' website at www.epigenomics.com
About Warnex
Warnex (www.warnex.ca) is a life sciences company devoted to 
protecting public health by providing laboratory services to the 
pharmaceutical and healthcare sectors. Warnex Analytical Services 
provides pharmaceutical and biotechnology companies with a variety of
quality control services, including chemistry, chromatography, 
microbiology, method development and validation, and stability 
studies. Warnex Bioanalytical Services specializes in bioequivalence 
and bioavailability studies for clinical trials. Warnex Medical 
Laboratories provides specialized testing for the healthcare industry
as well as pharmaceutical and central laboratory services. Warnex 
PRO-DNA Services offers DNA identification tests for paternity, 
maternity and other family relationships, as well as for immigration 
and forensic testing purposes. Warnex has three facilities located in
Laval and Blainville, Quebec, and Thunder Bay, Ontario.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS BY WARNEX
Certain statements contained in this news release are forward-looking
and are subject to numerous risks and uncertainties, known and 
unknown. For information identifying known risks and uncertainties, 
relating to financial resources, liquidity risk, key customers and 
business partners, credit risk, foreign currency risk, government 
regulations, laboratory facilities, volatility of share price, 
employees, suppliers, and other important factors that could cause 
actual results to differ materially from those anticipated in the 
forward-looking statements, please refer to the heading Risks and 
Uncertainties in Warnex's most recent Management's Discussion and 
Analysis, which can be found at www.sedar.com. Consequently, actual 
results may differ materially from the anticipated results expressed 
in these forward-looking statements.
Epigenomics legal disclaimers. This communication expressly or 
implicitly contains certain forward-looking statements concerning 
Epigenomics AG and its business. Such statements involve certain 
known and unknown risks, uncertainties and other factors which could 
cause the actual results, financial condition, performance or 
achievements of Epigenomics AG to be materially different from any 
future results, performance or achievements expressed or implied by 
such forward-looking statements. Epigenomics AG is providing this 
communication as of this date and does not undertake to update any 
forward-looking statements contained herein as a result of new 
information, future events or otherwise.
The information contained in this communication does not constitute 
nor imply an offer to sell or transfer any product, and no product 
based on this technology is currently available for sale by 
Epigenomics in the United States of America or Canada. The analytical
and clinical performance characteristics of any Epigenomics product 
based on this technology which may be sold at some future time in the
United States of America or Canada have not been established.
end of announcement                               euro adhoc

Further inquiry note:

Epigenomics AG
Dr. Achim Plum
Sen. VP Corporate Development
Tel: +49 30 24345 368
achim.plum@epigenomics.com

Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
München / free trade

Plus de actualités: Epigenomics AG
Plus de actualités: Epigenomics AG
  • 09.11.2010 – 08:46

    EANS-News: EPIGENOMICS AG Releases 9-Months Financial Report

    Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Company Information/9-month report/Molecular diagnostics Berlin, Germany, November 9, 2010 (euro adhoc) - Epigenomics AG (Frankfurt Prime Standard: ECX) reports today its third quarter and nine months financials for the period ended September 30, 2010. Key Financials | | ...